↓ Skip to main content

Effects of Candesartan on Left Ventricular Function, Aldosterone and BNP in Chronic Heart Failure

Overview of attention for article published in Cardiovascular Drugs and Therapy, February 2012
Altmetric Badge

Citations

dimensions_citation
11 Dimensions

Readers on

mendeley
30 Mendeley
Title
Effects of Candesartan on Left Ventricular Function, Aldosterone and BNP in Chronic Heart Failure
Published in
Cardiovascular Drugs and Therapy, February 2012
DOI 10.1007/s10557-012-6370-8
Pubmed ID
Authors

Aneta Aleksova, Serge Masson, Aldo P. Maggioni, Donata Lucci, Renato Urso, Lidia Staszewsky, Stefano Ciaffoni, Giuseppe Cacciatore, Gianfranco Misuraca, Michele Gulizia, Lucio Mos, Gianni Proietti, Calogero Minneci, Roberto Latini, Gianfranco Sinagra, on the behalf of the CandHeart Investigators

Abstract

PURPOSE: Heart failure (HF) is characterized by activation of neurohormonal systems such as aldosterone and natriuretic peptides. In the absence of published data, CandHeart trial was designed to assess the effects on left ventricular (LV) function, aldosterone and brain natriuretic peptide (BNP) of candesartan in patients with HF and preserved (LVEF ≥ 40%) or depressed (LVEF <40%) LV systolic function. METHODS: A total of 514 patients with stable symptomatic NYHA II-IV HF and any left ventricular ejection fraction (LVEF)were randomized to candesartan (target dose 32 mg once daily) as add-on therapy or standard medical therapy alone. Standardized echocardiographic exams were performed locally under central quality control, whereas biomarkers were assayed in a core laboratory. RESULTS: The majority of patients (73.3%) were NYHA II and on ACE inhibitors (91.8%) and beta-blockers (85.4%). Mean age was 66 ± 11 years. Mean LVEF was 36.2 ± 9.7% and 24.9% of patients had LVEF ≥ 40%. LVEF increased significantly more in the candesartan group (p = 0.09 at 12 weeks and p = 0.01 at 48 weeks) and left ventricular end-diastolic diameter decreased in candesartan group (p = 0.05 at 12 weeks). Candesartan significantly reduced aldosterone at 48 weeks (p = 0.009). BNP was reduced similarly over time in both study groups (p = 0.35 and p = 0.98 at 12 and 48 weeks, respectively). There were 6.6% of discontinuations of candesartan for adverse events. CONCLUSIONS: In CandHeart, the addition of candesartan to standard medical treatment did not reduce circulating BNP more than standard therapy (primary endpoint), but it significantly improved LV function and produced a marked decrease in aldosterone levels at study end.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 3%
Unknown 29 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 20%
Other 4 13%
Student > Bachelor 4 13%
Student > Master 4 13%
Student > Ph. D. Student 2 7%
Other 4 13%
Unknown 6 20%
Readers by discipline Count As %
Medicine and Dentistry 15 50%
Pharmacology, Toxicology and Pharmaceutical Science 2 7%
Psychology 2 7%
Agricultural and Biological Sciences 1 3%
Biochemistry, Genetics and Molecular Biology 1 3%
Other 2 7%
Unknown 7 23%